Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

Ó. Fernández, PS. Sörensen, G. Comi, P. Vermersch, HP. Hartung, L. Leocani, T. Berger, B. Van Wijmeersch, C. Oreja-Guevara

. 2024 ; 15 (-) : 1379538. [pub] 20240405

Language English Country Switzerland

Document type Journal Article, Review, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24014355

Multiple Sclerosis (MS) management in individuals aged 55 and above presents unique challenges due to the complex interaction between aging, comorbidities, immunosenescence, and MS pathophysiology. This comprehensive review explores the evolving landscape of MS in older adults, including the increased incidence and prevalence of MS in this age group, the shift in disease phenotypes from relapsing-remitting to progressive forms, and the presence of multimorbidity and polypharmacy. We aim to provide an updated review of the available evidence of disease-modifying treatments (DMTs) in older patients, including the efficacy and safety of existing therapies, emerging treatments such as Bruton tyrosine kinase (BTKs) inhibitors and those targeting remyelination and neuroprotection, and the critical decisions surrounding the initiation, de-escalation, and discontinuation of DMTs. Non-pharmacologic approaches, including physical therapy, neuromodulation therapies, cognitive rehabilitation, and psychotherapy, are also examined for their role in holistic care. The importance of MS Care Units and advance care planning are explored as a cornerstone in providing patient-centric care, ensuring alignment with patient preferences in the disease trajectory. Finally, the review emphasizes the need for personalized management and continuous monitoring of MS patients, alongside advocating for inclusive study designs in clinical research to improve the management of this growing patient demographic.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014355
003      
CZ-PrNML
005      
20240905134158.0
007      
ta
008      
240725e20240405sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2024.1379538 $2 doi
035    __
$a (PubMed)38646534
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fernández, Óscar $u Departament of Pharmacology, Faculty of Medicine; Institute of Biomedical Research of Malaga (IBIMA), Regional University Hospital of Malaga, Malaga, Spain $u Department of Pharmacology and Pediatry, Faculty of Medicine, University of Malaga, Malaga, Spain
245    10
$a Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review / $c Ó. Fernández, PS. Sörensen, G. Comi, P. Vermersch, HP. Hartung, L. Leocani, T. Berger, B. Van Wijmeersch, C. Oreja-Guevara
520    9_
$a Multiple Sclerosis (MS) management in individuals aged 55 and above presents unique challenges due to the complex interaction between aging, comorbidities, immunosenescence, and MS pathophysiology. This comprehensive review explores the evolving landscape of MS in older adults, including the increased incidence and prevalence of MS in this age group, the shift in disease phenotypes from relapsing-remitting to progressive forms, and the presence of multimorbidity and polypharmacy. We aim to provide an updated review of the available evidence of disease-modifying treatments (DMTs) in older patients, including the efficacy and safety of existing therapies, emerging treatments such as Bruton tyrosine kinase (BTKs) inhibitors and those targeting remyelination and neuroprotection, and the critical decisions surrounding the initiation, de-escalation, and discontinuation of DMTs. Non-pharmacologic approaches, including physical therapy, neuromodulation therapies, cognitive rehabilitation, and psychotherapy, are also examined for their role in holistic care. The importance of MS Care Units and advance care planning are explored as a cornerstone in providing patient-centric care, ensuring alignment with patient preferences in the disease trajectory. Finally, the review emphasizes the need for personalized management and continuous monitoring of MS patients, alongside advocating for inclusive study designs in clinical research to improve the management of this growing patient demographic.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x terapie $7 D009103
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a management nemoci $7 D019468
650    _2
$a komorbidita $7 D015897
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a věkové faktory $7 D000367
650    _2
$a stárnutí $x imunologie $7 D000375
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sörensen, Per Soelberg $u Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark $u Copenhagen and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Comi, Giancarlo $u Department of Neurorehabilitation Sciences, Multiple Sclerosis Centre Casa di Cura Igea, Milan, Italy $u University Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Vermersch, Patrick $u Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany $u Brain and Mind Center, University of Sydney, Sydney, NSW, Australia $u Department of Neurology, Palacky University Olomouc, Olomouc, Czechia
700    1_
$a Leocani, Letizia $u Department of Neurorehabilitation Sciences, Multiple Sclerosis Centre Casa di Cura Igea, Milan, Italy $u University Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Berger, Thomas $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria
700    1_
$a Van Wijmeersch, Bart $u University MS Centre, Hasselt-Pelt, Belgium $u Rehabilitation and Multiple Sclerosis (MS), Noorderhart Hospitals, Pelt, Belgium
700    1_
$a Oreja-Guevara, Celia $u Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain $u Department of Medicine, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 15 (20240405), s. 1379538
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38646534 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134152 $b ABA008
999    __
$a ok $b bmc $g 2143871 $s 1226221
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1379538 $e 20240405 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options